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The effects of primary tumors on the host systemic
environment and resulting contributions of the host
to tumor growth are poorly understood. Here, we
find that human breast carcinomas instigate the
growthof otherwise-indolent tumor cells,micrometa-
stases, and human tumor surgical specimens located
at distant anatomical sites. This systemic instigation
is accompanied by incorporation of bone-marrow
cells (BMCs) into the stroma of the distant, once-
indolent tumors. We find that BMCs of hosts bearing
instigating tumors are functionally activated prior to
their mobilization; hence, when coinjected with indo-
lent cells, these activated BMCs mimic the systemic
effects imparted by instigating tumors. Secretion of
osteopontin by instigating tumors is necessary for
BMC activation and the subsequent outgrowth of
the distant otherwise-indolent tumors. These results
reveal that outgrowth of indolent tumors can be
governed on a systemic level by endocrine factors
released by certain instigating tumors, and hold
important experimental and therapeutic implications.
INTRODUCTION
The tumor microenvironment has been the subject of intensive
investigation in recent years. A tumor-supportive role for many
of the host-derived stromal cells that form the tumor microenvi-
ronment has been demonstrated in a number of studies (Tlsty
and Coussens, 2006; Yang et al., 2008). For example, we and
others demonstrated that stromal fibroblasts and myofibroblasts994 Cell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc.within the tumor environment facilitate tumor growth and pro-
gression (Bhowmick et al., 2004; Olumi et al., 1999; Orimo
et al., 2005).
Far less is known about the contribution to tumor growth of the
host systemic environment. Several reports have shown that
assorted bone marrow-derived cells can be incorporated to
various extents into the tumor-associated stroma (Direkze and
Alison, 2006; Song et al., 2005; Udagawa et al., 2006). Most of
these studies suggest that bone marrow-derived cells support
tumor angiogenesis in one fashion or another, although the ex-
tent to which they do so is debated (Kopp et al., 2006; Lamagna
and Bergers, 2006).
While the presence of both locally and distantly derived cell
types has been observed in a number of tumors, it is not clear
whether tumors actively elicit stromal cell recruitment by directly
perturbing host cell reservoirs, such as the bone marrow (Shojaei
et al., 2007), or whether tumors are passive recipients of stromal
cell precursors that normally circulate throughout the body. We
therefore undertook to determine if engrafted human carcino-
mas actively perturb the host systemic environment as a means
of facilitating tumor outgrowth.
RESULTS
Primary Human Tumors Facilitate Growth
of Distant Indolent Tumors
In order to study systemic mechanisms that might facilitate
tumor progression, we constructed an in vivo experimental
model utilizing two human tumor cell lines. The first, termed
here an ‘‘instigator,’’ is the experimentally transformed human
mammary epithelial BPLER cell line (Ince et al., 2007), which
yields vigorously growing tumor xenografts that histopatho-
logically resemble invasive ductal adenocarcinomas commonly
encountered in breast cancer patients. These xenografts contain
abundant stroma, indicating that they are capable of recruiting
murine stromal cells. The second, termed here a ‘‘responder,’’
is the experimentally transformed human mammary epithelial
cell line, HMLER hygro-H-rasV12 (HMLER-HR) (Elenbaas
et al., 2001). Only 25% of the mice injected with these indolent
cells form observable tumors when examined 9 weeks after
implantation.
In an initial experiment, instigating BPLER tumor cells were
injected subcutaneously into the right flanks of Nude mice, while
indolent responding HMLER-HR cells were injected into the
contralateral flanks of these mice (Figure 1A). In a control group,
responder cells were injected contralaterally to Matrigel vehicle;
these responder cells did not form externally palpable tumors
during the subsequent experimental time period (Figure 1B);
however, after surgical exposure of the subcutaneous site at the
experimental end point, small masses were apparent in 20% of
the injected mice (Figure 1C).
In contrast, when the responder cells were injected opposite
instigating tumors, the responder cells formed actively growing
tumors after a lag phase of 40 days (Figure 1B), at which time
the instigating tumors were only 3.7 mm in diameter (Fig-
ure S1A). These responding tumors followed a progressive
increase in their growth that paralleled the growth of the contra-
Figure 1. Primary Human Breast Carcinomas Instigate
Growth of Distant Indolent Tumors
(A) Scheme of bilateral implantation system. Indolently growing
HMLER-HR transformed cells (Responders) are implanted sub-
cutaneously into one flank of host mice and either Matrigel control
or vigorously growing tumor cell lines (Instigators) are implanted into
the contralateral flank.
(B) In vivo growth kinetics of responder cells when implanted contra-
laterally to either Matrigel (blue) or BPLER instigators (red); n = 5 per
group.
(C) Final mass of responders from (B) 9 weeks after implantation oppo-
site either Matrigel or instigating BPLER tumors. Incidence of tumor
formation is shown above data bars; data include injections not result-
ing in responding tumor growth.
(D) In vivo growth kinetics of responders when injected 30 days after
implantation of either Matrigel plugs (blue) or instigating BPLER tumor
cells (red); n = 5 per group.
(E) Average final mass of responding tumors from (D) recovered oppo-
site either Matrigel or BPLER instigators; incidence of responder
tumor formation is indicated above data bars.
(F) Final mass of responding tumors recovered opposite Matrigel or
indicated tumor cell lines 9 weeks after implantation. Incidence of
responding tumor formation is indicated above bars; data include
mice from three separate experiments. Mass of responders recovered
opposite Matrigel is significantly different from those opposite 231
(p = 0.031) and BPLER (p = 0.039).
lateral instigating tumors (Figure S1A). The average final
mass of these responding tumors was 10-fold that of
the responding cell plugs recovered opposite Matrigel,
and the incidence of responding tumor formation was in-
creased from 20% to 100% (Figure 1C). We confirmed
that instigating cells did not metastasize to sites of re-
sponding cell implantation and that the neoplastic cells
in the responding tumors were derived exclusively from
responder cells (Figures S1D and S1E).
We also determined that instigating tumors established a sup-
portive systemic environment soon after their implantation.
Thus, when responding cells were implanted following 30 days
of instigating BPLER tumor growth, the first palpable responding
tumors were evident 5 days later (Figure 1D). Notably, the insti-
gating tumors were only2 mm in diameter when the responder
cells were injected, and the growth of responding tumors was
accompanied by a constant rate of growth of the contralateral
instigating tumors (Figure S1B). The average mass of these re-
sponding tumors was10-fold greater than that of the responder
cell plugs recovered opposite Matrigel (Figure 1E). Moreover,
the presence of contralateral instigating tumors increased the
incidence of responder tumor formation from 25% to 80%.
In a set of in vitro cell culture experiments, we determined that
the conditioned media taken from instigating BPLER tumor cells
did not alter the growth rate of responding HMLER-HR cells
(data not shown). These findings suggested that the outgrowth
of responding tumors in vivo was not a consequence of instigat-
ing tumor-derived growth factors stimulating responder cell
proliferation.
We next asked whether the capacity for systemic instigation
was unique to the BPLER cell line. We found that MDA-
MB-231 human breast cancer cells (231) also instigatedCell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc. 995
HMLER-HR responding tumors that were 25-fold larger than
those injected opposite Matrigel (Figure 1F); as before, the
neoplastic cells in responding tumors were formed exclusively
from the HMLER-HR responders (Figure S1E). In contrast, three
other vigorously growing tumor types all failed to instigate re-
sponder tumor growth (Figure 1F). Hence, the ability to system-
ically instigate indolent tumor outgrowth was uncoupled from the
ability of transformed cells to form vigorously growing primary
tumors.
Examination of tissues recovered from responding cell injec-
tion sites located opposite Matrigel plugs revealed a high degree
of necrosis (Figure S1C). Responding tumors growing opposite
instigating BPLER or MDA-MB-231 tumors, however, closely re-
sembled adenocarcinomas (Figure S1C). The latter observations
indicated that instigating tumors have a profound systemic effect
on both the viability and histopathology of distantly located
responding tumors.
Incorporation of Bone Marrow-Derived
Cells into Instigated Tumors
Vigorous growth of responding tumors occurred only when the
responder cells were implanted contralaterally to instigators
in vivo. This fact, taken together with reported observations
that certain types of stromal cells have origins in the bone mar-
row (Direkze and Alison, 2006), caused us to speculate that insti-
gating tumors might mobilize stromal cell precursors from the
bone marrow into the circulation, thereby making them available
for recruitment by responding tumors.
In order to determine whether instigating tumors mediated re-
cruitment of bone marrow cells (BMC) into the responding tumor
stroma, we transplanted BMCs from immunocompromised mice
Figure 2. Bone Marrow-Derived Cells Are Incorpo-
rated into Responding Tumor Stroma
(A) Indicated tumor cells were injected into mice that had
previously been engrafted with GFP+ BMCs.
(B) Whole mount fluorescence photomicrographs to visualize
GFP+ BMCs recruited to indicated tumors and control tissues
4 weeks after tumor cell injections; scale bar = 2 mm. Average
mass of all tissues is indicated; n = 10 mice per group.
(C) Average contribution of GFP+ cells as a percentage of total
cells (flow cytometric analysis); n = 7 tumors/tissues per
group. Responding tumors opposite BPLER instigators incor-
porated significantly more GFP+ BMCs than those opposite
Matrigel (p = 0.039) and PC3 noninstigating tumors (p =
0.042); responders were not statistically different from their
contralateral BPLER instigators; instigating BPLER tumors
were not statistically different from noninstigating PC3 tumors.
that ubiquitously express green fluorescent protein
(Rag1/EGFPTg mice) into irradiated mice that
were used as hosts in subsequent experiments.
After confirming successful engraftment of GFP+
BMCs (Figure S2A), various human tumor cells
were implanted into these mice using the contra-
lateral injection protocol (Figure 2A).
Responder growths were surveyed for GFP+
BMC incorporation 4 weeks after tumor cell injec-
tions, a time when all xenografted masses were of
comparable size (10 mg, 0.04% total body weight;
Figure 2B). This time period was dictated by previous observa-
tions that small responder cell plugs implanted opposite non-
instigating tumor cells could be recovered within 4 weeks of
their initial implantation, but thereafter, were no longer visible
at the injection site (data not shown).
Incorporation of GFP+ BMCs into responder grafts injected
opposite Matrigel (10% ± 4%) were not statistically significantly
greater than those of control subcutaneous tissues taken from
mice that had been transplanted with GFP+ BMCs but had not
been injected with tumor cells (3% ± 3%; Figure 2C). Moreover,
in spite of the significant recruitment of GFP+ BMCs to noninsti-
gating PC3 tumors (28% ± 2%), contralateral responding grafts
failed to incorporate GFP+ cells to any extent above that of con-
trols (10% ± 3%; Figure 2C). In contrast, GFP+ cells accounted
for 23% of the total cells present in the responding tumors
growing opposite BPLER-instigating tumors, which were com-
prised of 27% GFP+ cells (Figure 2C).
We also analyzed incorporation of GFP+ BMCs into tumors
that had grown as xenografts for 9 weeks in such host mice.
The responding tumors were comprised of 24% GFP+ BMCs,
while the contralateral instigating tumors consisted of 31%
GFP+ BMCs (Figures S2B and S2C). These results indicated
that the contribution of bone marrow-derived cells to both
instigating and responding tumor stroma remained relatively
constant during tumor growth. Moreover, the fact that certain
noninstigating tumors, despite their own rapid growth and
BMC recruitment, were unable to mobilize BMCs to the stroma
of the contralateral responders, suggested that only instigating
tumors could provide the distant responding tumors with stromal
cells that they require for growth.996 Cell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc.
Figure 3. Instigators Functionally Activate the Bone Marrow
(A) Experimental scheme for implantation of BMCs/responding tumor cell admixtures.
(B) Average mass of resulting tumors 12 weeks after implantation of mixtures of responder cells with indicated BMCs. Tumor incidence is indicated above bars;
data represent mean of four separate experiments. p = 0.012 comparing BM-I with responders alone; p = 0.015 comparing BM-I with BM-C; p = 0.001 comparing
BM-I with BM-NI.
(C) Hematoxylin and Eosin stain to visualize histopathology of resulting tumors/tissues; scale bar = 400 mm.Instigating Tumors Functionally Activate the Bone
Marrow Prior to Mobilization of Cells
The above results suggested that instigating tumors might
perturb the bone marrow, mobilizing BMCs into the circulation
that then become available for recruitment by responding tu-
mors. We therefore devised a test to determine whether there
were ascertainable functional differences between the BMC
populations of various types of tumor-bearing hosts. We isolated
BMCs from mice bearing either instigating BPLER tumors or
size-matched, noninstigating PC3 tumors and mixed each of
these BMC populations with responder cells prior to injection
(Figure 3A). As controls, we mixed responder cells with BMCs
from mice bearing only Matrigel plugs. We then gauged the rel-
ative abilities of these various admixed BMC populations to pro-
mote responder tumor growth over a period of 12 weeks. We
confirmed that instigating tumor cells were absent from the
BMC populations used in these experiments (Figures S3A and
S3B).
When mixed with responder cells, BMCs from control, nontu-
mor bearing mice (BM-C) and from mice bearing noninstigating
PC3 tumors (BM-NI) both failed to enhance responder tumor
growth to any significant extent (Figure 3B). Histological obser-
vation of the resulting masses revealed either large necrotic
areas or only small clusters of apparently viable cells (Figures
3Ca and 3Cc). However, admixture of BMCs from mice bearing
BPLER-instigating tumors (BM-I) greatly enhanced both the sizeand incidence of responder tumor formation (Figure 3B); these
tumors formed with a histopathology similar to that of respond-
ing tumors growing opposite instigating tumors (Figure 3Cb).
Moreover, in a separate set of experiments, mixing BMCs from
instigator-bearing Rag1/EGFPTg mice with responder cells
revealed that the admixed GFP+ marrow-derived cells were re-
tained within the responding tumor stroma after 9 weeks of
growth (Figure S3C).
We also functionally tested BMCs prepared from mice bearing
relatively small instigating BPLER tumors (20–60 mg) and found
that even these admixed BMCs enhanced responding tumor for-
mation compared with control BMCs (Figure S3D). These results
indicated that instigating tumors as small as 20 mg—only
0.08% of total body weight—are capable of functionally acti-
vating the bone marrow and extended our earlier results by dem-
onstrating that instigating tumors established a tumor-promoting
systemic environment relatively early in their growth. Moreover,
since the admixed BMCs from instigator-bearing mice recapitu-
lated the effects of an implanted instigating tumor, we concluded
that most if not all of the tumor-promoting effects of systemic in-
stigation are achieved via endocrinal perturbation of the host
bone marrow.
Instigators Perturb Primitive Hematopoietic BMCs
In order to determine how instigating tumors might affect bone
marrow physiology, we analyzed the hematopoietic cell typesCell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc. 997
in the marrow of these immunocompromised host mice. When
we surveyed expression of a number of cell-surface antigens, in-
cluding CD11b, CD45, Gr1, VEGFR1, VEGFR2, and CD31, we
detected no significant changes in the representation of cell
types in the marrow of the instigator-bearing mice, as compared
to Matrigel-bearing mice (data not shown). However, we repeat-
edly observed a subtle yet significant decrease in the frequency
of Lin/Sca1+/cKit+ (LSK) cells in the marrow of mice bearing in-
stigating tumors when compared with mice bearing only Matrigel
plugs (Figure 4A). Such LSK cells have been shown by others to
contain the hematopoietic stem cells in mice (Kondo et al., 2003).
This decrease in the LSK population was not manifest in the bone
marrow of mice bearing noninstigating PC3 tumors (Figure 4A).
In separate experiments, we saw similar reductions in the LSK
population in the marrow of mice bearing BPLER-instigating
tumors when compared with mice injected only with Matrigel
(Fig S4A).
Bone marrow-derived hematopoietic cells have been ob-
served within primary tumor stroma and are thought to play
a role in promoting tumor progression (Kopp et al., 2006). Ac-
cordingly, we undertook to determine whether the observed de-
crease in LSK cells in the bone marrow correlated with the pres-
ence of Sca+/cKit+ hematopoietic cells in the responding tumor
stroma. To do so, we measured the cell-surface expression of
Sca1 and cKit on the GFP+ bone marrow-derived cells present
in 4 week responding tumor masses that were implanted contral-
aterally to either BPLER instigators or PC3 noninstigators.
The contribution of primitive Sca1+/cKit+ cells to the total
GFP+ bone marrow-derived responder stromal compartment
was minimal and equivalent between the two groups (3%;
Figure 4B). We found, instead, that the majority of the GFP+/
Sca+ bone marrow-derived cells were negative for cKit and
Figure 4. Instigating Tumors Perturb BoneMarrow
Lin/Sca1+/cKit+ (LSK) Cells while Sca1+/cKit
Cells Are Incorporated into Responding Tumors
(A) Flow cytometric analysis of LSK cells in the bone mar-
row of various tumor-bearing mice; n = 4 per group.
(B) Quantification of Sca1+/cKit+ and Sca1+/cKit cells as
percentage of total GFP+ cells in responding tumors
recovered opposite instigating BPLER tumors (red) or
noninstigating PC3 tumors (gray); n = 7 per group.
(C) Merged photomicrographs of indicated responding
tumors stained for GFP (green), Sca1 (red), and cell nuclei
(blue); GFP+/Sca1+ cells appear yellow (arrows); scale
bar = 25 mm.
that these Sca1+/cKit cells comprised 66%
of the GFP+ cells recruited to the responding
tumors that had grown opposite instigating
tumors; the GFP+ cells from indolent cell clus-
ters recovered opposite noninstigators con-
tained only 38% of these Sca1+/cKit cells
(Figure 4B). Cells in the bone marrow that are
Sca1+/cKit have been described as a quies-
cent population of hematopoietic progenitor
cells that are resistant to the cytotoxic effects
of 5-FU and, under certain conditions, have
reconstitution capability (Klarman et al., 2003; Randall and
Weissman, 1998).
Upon immunohistological examination of responding tumors
for the colocalization of GFP and Sca1 antigens, we found that
bone marrow-derived GFP+/Sca1+ cells (which were almost en-
tirely cKit, see above) were rarely observed in the responder cell
plugs recovered opposite Matrigel or noninstigating tumors and,
when present, were localized largely near blood vessels of the
normal skin (Figures 4Ca and 4Cc). In contrast, when growing
opposite instigating tumors for either 4 or 8 weeks, bone
marrow-derived GFP+/Sca1+ cells were found intermingled
with the neoplastic HMLER-HR responding cells (Figures 4Cb
and S4B).
Collectively, these results demonstrate that instigating tumors
specifically decrease the primitive hematopoietic cell compart-
ment (LSK) in the host marrow. This perturbation is not associ-
ated with a concomitant recruitment of Sca1+/cKit+ cells to the
responding tumor stroma but, rather, correlates with enhanced
recruitment of Sca1+/cKit cells into the responding tumor
stroma.
Tumor-Derived Osteopontin Is Necessary
for Systemic Instigation
We wished to learn how instigating tumors communicate with
the host bone marrow. We therefore analyzed the plasma of
mice bearing instigating tumors, noninstigating tumors, or Matri-
gel control plugs in order to determine whether we could detect
alterations in the levels of various human cytokines that were
secreted by the engrafted tumor cells (Table S1). There were
no significant differences in the plasma levels of 80 distinct hu-
man cytokines in mice bearing instigating tumors compared
with those bearing noninstigating tumors (data not shown),998 Cell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc.
with one exception: osteopontin (hOPN). In an initial experiment,
plasma levels of tumor-derived hOPN in mice bearing instigating
tumors were elevated 3-fold relative to noninstigating tumors
(data not shown).
Osteopontin (OPN) is a secreted glycoprotein having pleiotro-
pic effects on inflammation, angiogenesis, fibrosis, and tumor
metastasis, and carries functional domains that are conserved
across mouse and human species. (Cook et al., 2005). A number
of studies have shown that OPN is secreted in a soluble form by
a variety of tumor cell types and is elevated in the blood of many
cancer patients with metastatic disease (Mor et al., 2005; Tuck
et al., 2007); however, such studies have not revealed a physio-
logic role for circulating OPN in tumor pathogenesis.
We therefore expanded our analysis of plasma hOPN to
include mice bearing various instigating and noninstigating
tumors. Plasma levels of tumor-derived hOPN in mice bearing
instigating tumors—BPLER and MDA-MB-231—were elevated
at least 2.2-fold, and up to 2.6-fold, above those of control
mice injected with either HMLER-HR responders or noninstigat-
ing PC3 tumors (Figure 5A). In contrast, there were no significant
differences in plasma hOPN levels between mice injected with
the responding cells and those injected with PC3 noninstigating
Figure 5. Tumor-Derived Osteopontin (hOPN) Is
Necessary for Systemic Instigation
(A) Concentration of hOPN in plasma of mice 9 weeks after
injection of indicated cells; n = 14 for responder group; n = 5
for all other groups. Plasma OPN was significantly elevated
in mice bearing BPLER (p = 0.02) and 231 (p = 0.01) tumors
compared with plasma from mice injected only with responder
cells.
(B) The left shows in vivo growth kinetics of instigating MDA-
MB-231 (parental), control 231 cells expressing shRNA
against Luciferase (shLucif), and 231 derivatives expressing
shRNAs against hOPN; n = 9 for parental group; n = 5 for all
other groups. The right shows in vivo growth kinetics of the
responding cells injected opposite the indicated tumor cell
lines.
(C) Flow cytometric analysis of LSK cells in the bone marrow of
mice with indicated bilateral tumors; n = 4 per group.
(D) Admixtures of responder cells with BMCs from mice bear-
ing 231 instigators yielded tumors that were significantly larger
than those resulting from admixtures of BMCs from mice bear-
ing shOPN 1 tumors (p = 0.030), shOPN 5 tumors (p = 0.047),
or responder cells alone (p = 0.026); n = 4 per group.
tumors (Figure 5A). We also determined that
none of the tumor types that we implanted al-
tered the plasma levels of murine osteopontin
(Figure S4C).
The relative increases in plasma hOPN that we
observed in instigator-bearing mice were compara-
ble to increases that we observed in the plasma of
patients with metastatic breast cancer compared
to cancer-free subjects (2.2- to 2.8-fold; Figure
S4D). Indeed, these elevations are consistent with
previously published reports and are considered
to represent a clinically significant parameter that
is associated with reduced patient survival (Furger
et al., 2001).
OPN is reported to restrict LSK numbers in the bone marrow
through its actions on the hematopoietic cell niche as well as
on the LSK cells themselves (Nilsson et al., 2005; Stier et al.,
2005); this was reminiscent of the decline in LSK numbers we ob-
served in the marrows of mice bearing instigating tumors
(Figure 4A). Furthermore, hematopoietic stem cells express the
OPN receptors, CD44 and a4 integrin, and the differentiation sta-
tus of these cells can be altered by OPN signaling (Iwata et al.,
2004; Schmits et al., 1997; Scott et al., 2003).
We therefore tested the notion that circulating hOPN released
by instigating tumors perturbs the host bone marrow, thereby fa-
cilitating systemic instigation. In order to do so, we suppressed
hOPN expression in MDA-MB-231 (231) instigating tumor cells
using shRNA; such suppression would presumably allow us to
determine whether OPN deficiency would affect their ability to
function as instigators. We identified two shRNA constructs
that reduced OPN secretion at least 23-fold and did not signifi-
cantly alter either cell morphology or growth kinetics in culture
(Figures S5A–S5D).
We injected either 231 cells or their OPN-deficient derivatives
contralaterally to HMLER-HR responder cells in order to gauge
the ability of these 231 variants to function as instigators. WeCell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc. 999
observed that OPN deficiency did not impair in vivo growth kinet-
ics of implanted instigating 231 cells in which the shRNAs were
expressed (Figures 5B [left] and S5E). As expected, the parental
231 tumors, as well as control tumors expressing shRNA against
luciferase, instigated growth of contralateral responding tumors
(Figure 5B; right). In striking contrast, responding tumors did not
grow when the contralateral 231 tumors were deficient for OPN
(Figure 5B; right). Hence, despite the fact that OPN-deficient 231
cells continued to form vigorously growing tumors, OPN defi-
ciency abolished their instigating ability.
We used mice engrafted with GFP+ BMCs to determine
whether suppressing OPN in instigating tumors had any effect
on incorporation of BMCs into the contralateral responder cell
plugs. Responder tumors grown opposite the parental 231 insti-
gators were comprised of 28% bone marrow-derived cells,
while responder cell plugs recovered opposite OPN-deficient
tumors contained only 3% GFP+ bone marrow-derived cells
(Figure S5F).
The reduction in LSK cells that was reproducibly observed in
the mice bearing parental 231 instigating tumors was absent in
mice bearing OPN-deficient 231 tumors (Figure 5C). Moreover,
when we mixed responding BMCs from mice bearing OPN-
deficient 231 tumors with responding cells prior to injection,
responding tumor growth was not facilitated, whereas the
admixed BMCs from mice bearing the parental 231 tumors, as
before, supported tumor growth (Figure 5D). These results indi-
cate that instigating tumor-derived OPN is required to perturb
the host bone marrow in order to mediate systemic instigation.
Finally, we expressed hOPN in the noninstigating PC3 cells
(PC3OPN), which normally secrete hOPN to negligible levels
(Figures S5B and S6A), in order to determine whether hOPN
expression might confer upon these cells an ability to system-
ically instigate responder growth. We identified a population of
PC3OPN cells that secreted hOPN at levels comparable to
those of the instigating 231 cells and demonstrated growth
kinetics that were no different from the parental PC3 cells
in vitro (Figures S6A–S6C). These PC3OPN cells were therefore
implanted into host mice contralaterally to the responder cells.
Although hOPN concentrations in the plasma of mice bearing
the PC3OPN tumors were comparable to those of instigator-
bearing mice (Figure S6D), and both PC3 parental and
PC3OPN tumors grew with similar kinetics in vivo (Figure S6E;
left), the PC3OPN tumors, like the PC3 parental tumors, did
not instigate outgrowth of the contralateral responder cells
(Figure S6E; right). Collectively, these results reveal that OPN
secretion, while necessary, is not sufficient for systemic
instigation.
Systemic Instigation of Metastatic Outgrowth
Taken together, these observations suggested that mechanisms
of systemic instigation might also serve to facilitate the out-
growth of disseminated metastatic cells. To test this notion, we
used a model of experimental metastasis to gauge the effects
of systemic instigation on this process. Accordingly, we simulta-
neously injected GFP instigating BPLER tumor cells into subcu-
taneous sites and GFP+ MDA-MB-231 cells (231+GFP) into the
tail veins of mice (Figure 6A). These 231+GFP cells, which serve
as responders in these experiments, are only weakly metastatic,1000 Cell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc.and nearly 90% of the cells are cleared from the lungs within
1 day of intravenous injection (data not shown).
There was no significant difference between mice bearing
subcutaneous instigating tumors and those bearing only Matri-
gel plugs when the numbers of 231+GFP micrometastatic lung
foci were counted at days 2 and 16 following injections
(Figure 6B). Furthermore, the numbers of lung metastases
decreased between days 2 and 16 in both groups, even though
instigating tumors had started to grow within this time period
(Figure 6B). These results suggested that the presence of a grow-
ing instigating tumor at a distant site did not affect the initial sur-
vival or retention of the weakly metastatic cells in the lungs of
host mice.
In stark contrast, at the 30 and 84 day time points, the numbers
of 231+GFP foci in the lungs of mice bearing primary subcutane-
ous instigating tumors were elevated 3- and 9-fold, respectively,
over the basal level of foci observed in lungs of control mice (Fig-
ures 6B, 6C, and S7A). Importantly, no instigating BPLER cells
were observed in these instigated lung foci, indicating that the
lung metastases were derived from the responding 231+GFP
cells (Figures 6D and S7B). Moreover, we observed Sca1+ cells
intermingled with metastatic tumor cells only in the presence of
subcutaneous instigating tumors (Figure S7C). These data indi-
cate that primary instigating tumors had a profound systemic
effect on the outgrowth of otherwise-weakly metastatic cells
that were present in the lungs.
We next tested whether OPN was necessary for the effect of
primary instigating tumors on the outgrowth of lung metastases
in a model that mimics dissemination of metastatic cells from
a primary tumor. Accordingly, we injected either Matrigel, the pa-
rental GFP 231 cells, or GFP 231-shOPN cells, into subcuta-
neous sites and, at the same time, injected the weakly metastatic
231+GFP cells into the tail vein of hosts. Lungs were examined
4 weeks later—a time prior to which the parental 231 cells are
capable of metastasizing to the lungs from subcutaneous sites
(data not shown).
As before, the presence of subcutaneous instigating tumors
enhanced the numbers of 231+GFP lung micrometastases
nearly 3-fold when compared to lungs of mice bearing only
Matrigel plugs (Figure 6E). Importantly, subcutaneous OPN-
deficient tumors lost their ability to enhance lung metastases
(Figure 6E). Moreover, macrometastases were present in 100%
of the lungs from mice bearing subcutaneous instigating tumors,
while none of the mice bearing tumors deficient for OPN had
macrometastatic lung tumors (Figure 6F). The average primary
subcutaneous tumor burden was approximately equivalent in
both groups of mice; these tumors were small (40 mg) and rep-
resented 0.16% of total body mass (Figure 6E). These data
demonstrate that secretion of OPN is necessary for the ability
of instigating tumors to systemically instigate outgrowth of dis-
tant responding tumor cells, independent of whether they are im-
planted into subcutaneous sites or have arrived in the lungs via
the circulation.
Systemic Instigation of Human Colon
Tumor Surgical Specimens
The present results demonstrate that actively growing tumors,
even when relatively small, can exert systemic effects that are
sufficient to induce distantly implanted, transformed cells to
progress from an indolent state to one yielding vigorous tumor
growth. We were therefore curious if systemic instigation could
be used to facilitate the growth of human tumor surgical speci-
mens. Some surgical samples of human tumors are capable of
growing as xenografts after serial passage through SCID mice
(Hylander et al., 2005; Naka et al., 2002), while the majority of
human tumors samples are incapable of doing so. Accordingly,
in order to select a human tumor sample that would serve as
an indolent responder in our systemic instigation model, we
first screened a number of surgical samples for their growth as
xenografts in SCID mice.
In all of these experiments, we prepared 2 mm fragments of
tumors that were surgically removed from patients with colon
cancer and implanted them beneath the skin of SCID mice
(Figure S8A). After two serial passages through the mice, we
identified a patient tumor xenograft that exhibited slow growth
kinetics and yielded histopathology involving widespread necro-
sis (Figure S8B). This tumor sample was therefore designated as
Figure 6. Instigating Tumors Instigate Out-
growth of Disseminated Lung Metastases
(A) Model of metastatic systemic instigation: GFP in-
stigating tumor cells (1 tumor) or Matrigel control are
subcutaneously (s.c.) injected into both flanks of host
mice while weakly metastatic GFP+ tumor cells are
injected intravenously (i.v.).
(B) Average numbers of micrometastatic lung foci after
concurrent injection of weakly metastatic 231 cells
i.v. and either instigating BPLER tumors or Matrigel
control plugs s.c.; n = 4 mice per group.
(C) Whole-mount fluorescent photomicrographs of
231+GFP responder lung foci in mice bearing either
Matrigel control plugs (a, b) or GFP instigating 1
tumors (c, d); scale bar = 0.5 mm.
(D) Immunohistochemical staining of lung sections for
GFP+ responder cells (red); nuclei stain, blue; scale
bar = 200 mm.
(E) For (E) and (F), mice received s.c. injections of
either Matrigel, GFP parental 231 cells or GFP
shOPN 231 cells and i.v. injection of weakly metastatic
231+GFP cells. Graph depicts numbers of micro-
metastatic 231+GFP lung foci from each mouse after
4 weeks; lines denote average number of foci per
group; average 1 tumor burden is indicated. Whole-
mount fluorescent photomicrographs depict micro-
metastatic foci (arrows); scale bar = 0.5 mm.
(F) Numbers of macrometastatic 231+GFP foci
counted by eye in the lungs of each mouse. Whole-
mount images of lungs are shown with corresponding
fluorescent images; scale bar = 2 mm.
a candidate responder in our systemic insti-
gation model. Consequently, 1–2 mm frag-
ments of this human colon carcinoma xeno-
graft were implanted subcutaneously into
NOD-SCID mice contralaterally to either
Matrigel or to instigating BPLER human
mammary carcinoma cells.
Segments of the colon tumor that were
implanted contralaterally to Matrigel were
unable to grow during the 40 day experimental time period
(Figure 7A; left). In striking contrast, all of the colon tumor seg-
ments (three of three) implanted contralaterally to the BPLER
instigators displayed robust growth kinetics; growth of these
responding colon tumor specimens was first observed 27 days
after implantation and lagged the first growth of the contralateral
instigators by only 15 days (Figure 7A; center). As a control, we
determined that neither of the responder types—HMLER-HR
responder or colon surgical sample responder—could instigate
the growth of the other when implanted contralaterally (Figure 7A;
right).
The responding colon tumors that grew opposite instigating
BPLER tumors displayed histopathology consistent with that of
adenocarcinomas (Figure 7B), and the associated neoplastic
cells were actively proliferating (Figure 7C). As before, Sca1+
cells were observed in these tumor stromata and were localized
near areas of proliferating tumor cells (Figure S8C).
These findings hold at least two implications. First, mammary
tumors can act across tissue lineages to systemically instigateCell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc. 1001
growth of colon tumors, indicating the generality of this physio-
logic signaling. Second, the presently described procedure, or
derivatives thereof, can be used to study the growth of some
human tumor specimens and tumor cell lines that might other-
wise grow very slowly or not at all as xenografts in vivo.
DISCUSSION
The mechanisms of systemic instigation presented here operate
in a fashion opposite to that occurring when primary tumors
release antiangiogenic factors, which function to suppress
metastatic outgrowth (Gohongi et al., 1999; O’Reilly et al.,
1994, 1997). Moreover, systemic instigation is quite different
from more recently reported processes by which primary murine
tumors affected the host lung environment prior to the dissemi-
nation of metastatic tumor cells (Hiratsuka et al., 2002, 2006;
Kaplan et al., 2005). The work presented here, instead, describes
the ability of instigating tumors, even when relatively small (less
than 0.08% of total body mass), to facilitate outgrowth of
already-established, otherwise-indolent tumor cells located at
distant sites (Figure 7D). At present, it is unclear which of these
systemic signaling mechanisms is more likely to govern the be-
Figure 7. Human Colon Tumor Surgical Specimen
Responds to Systemic Instigation
(A) The left shows human colon tumor segments (‘‘colon re-
sponder’’; blue line) dissected from a single patient’s surgical
specimen and implanted opposite Matrigel plugs (gray line).
The center shows in vivo growth kinetics of colon responder
tumor segments (blue line) implanted opposite instigating
BPLER breast carcinoma cells (red line). The right shows
that neither the human colon tumor segments (blue line) nor
the HMLER-HR breast responder cells (orange line) are able
to grow when implanted opposite one another. n = 3 mice
per group.
(B) Hematoxylin and Eosin stain of a colon responder recov-
ered opposite a breast instigator, scale bar = 50 mm.
(C) Staining for Ki67 (brown) to reveal proliferating responding
colon tumor cells implanted opposite BPLER breast instiga-
tors, scale bar = 50 mm.
(D) Model of Systemic Instigation: Instigating tumors secrete
osteopontin (OPN), which perturbs primitive hematopoietic
cells in the host bone marrow; cells in the bone marrow are
functionally activated prior to mobilization into the circula-
tion; release of activated bone marrow-derived cells into the
circulation and their subsequent incorporation into distant
responding tumor stroma serve to foster outgrowth of the
once-indolent cells into growing adenocarcinomas.
havior of commonly occurring human tumors, as
remarkably little is known about the effects of
primary tumors on their hosts and on derived
metastases.
The relevance of OPN expression to human can-
cer pathogenesis has been revealed by studies
showing that OPN levels are elevated in aggressive
tumors types when compared with counterpart
normal tissue or low-grade tumors, correlates
with the presence of metastatic disease, and is
included among lists of genes that predict poor prognosis in
patients with various types of cancer (Graudens et al., 2006;
Minn et al., 2005; Richardson et al., 2006; van de Vijver et al.,
2002). Yet, other studies have shown that soluble OPN is de-
tected at elevated levels in the blood of many cancer patients
with metastatic disease (Ramankulov et al., 2007; Tuck et al.,
2007). Despite these findings, the mechanism by which OPN
supported metastasis was not clear.
It had been reported that OPN deficiency does not affect the
growth of certain primary tumors, yet it significantly reduced their
metastatic potential (Cook et al., 2005; Feng and Rittling, 2000;
Wai et al., 2005). In these earlier reports, the ability of OPN to
enhance cell motility and invasion in vitro was presented as
one explanation for the role of OPN in furthering metastasis.
Here, however, we identify an alternative, novel role for tumor-
derived OPN in supporting distant tumor outgrowth: release of
soluble OPN enables instigating tumors to communicate with
and perturb the bone marrow. Indeed, BMCs from hosts bearing
OPN-deficient tumors, unlike their OPN-secreting counterparts,
were not functionally activated to support tumor growth when
admixed with responder cells, indicating that instigator-derived
circulating OPN is acting on the bone marrow rather than directly1002 Cell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc.
on the distantly located responder cells. Our observations that
forced hOPN expression was not sufficient to convert non-
instigators into instigators suggest that other, still-unidentified
instigator-specific factors cooperate with hOPN to promote sys-
temic instigation. Nonetheless, the fact that hOPN is necessary
for all of the currently identified aspects of systemic instigation
supports the notion that OPN signaling is an attractive therapeu-
tic target (Rittling and Chambers, 2004).
Other studies first alerted us to the possibility that OPN signal-
ing might mediate at least part of the systemic instigation mech-
anism. Such studies demonstrated that OPN signaling regulates
the fate of primitive hematopoietic cells in vitro and perhaps
more importantly, that OPN/ mice have significantly elevated
levels of LSK cells in their bone marrow (Iwata et al., 2004; Nils-
son et al., 2005; Stier et al., 2005). While our results generally
concur with these studies, our observations do not reveal
whether the significant incorporation of Sca1+/cKit bone mar-
row-derived cells into the instigated tumor stroma is directly
related to the reduction in marrow LSK cell numbers that we ob-
served. In fact, little is known about Sca1+/cKit cells; they have
been referred to as a ‘‘mystery population’’ in the bone marrow
(Randall and Weissman, 1998). In any event, our results provide
evidence that bone marrow functional activation can be gov-
erned on a systemic level by endocrine factors that are released
by certain instigating tumors. These results therefore move
beyond existing studies, which largely address bone marrow
cell recruitment to primary tumors.
The ability of instigating tumors to foster the growth of a human
colon tumor surgical specimen underscores the powers of sys-
temic instigation. Indeed, to our knowledge, methods to expe-
dite the growth of human tumor surgical specimens in vivo
have not been previously described. These results suggest
that the presently described procedure can be used to study
aspects of human tumor biology that would otherwise be difficult
if not impossible to study. In the longer term, identification of
additional tumor-derived factors that perturb the host systemic
environment in one way or another may allow one to predict
the effects that a given primary tumor type has on the out-




Generation of HMLER hygro-H-rasV12 and BPLER human mammary epithelial
tumor cells has been described (Elenbaas et al., 2001; Hahn et al., 1999; Ince
et al., 2007). EpH4Ras murine mammary carcinoma cells were a gift from
E. Reichmann (Oft et al., 1996). Human mammary carcinoma MDA-MB-231,
human prostate carcinoma PC3, and murine Lewis lung carcinoma LLC
were obtained from the ATCC (Manassas, VA) and cultured under standard
conditions.
Animals and Tumor Xenografts
Female Nude mice were purchased from Taconic (Hudson, NY); a colony of
NOD-SCID mice was maintained in-house. All experiments were performed
in accordance with regulations of MIT Committee on Animal Care protocol
(1005-076-08). Tumor cells were injected subcutaneously into nonirradiated
mice (see Supplemental Data) and tumor diameter was measured on the flanks
of live Nude mice using calipers; volume was calculated as 4/3Pr3.Bone Marrow Harvest and Transplantation
BMCs were harvested from donor mice by flushing femurs with sterile Hanks’
balanced salt solution (HBBS; GIBCO) with penicillin/streptomycin/fungisone.
Cells were washed 23 with sterile HBBS, dissociated with 18 g needles, and
filtered through 70 mm nylon mesh. For transplantation experiments, 2 3 106
BMCs fromRag1/xEGFPTg donor mice were injected into the retroorbital si-
nus 8–10 hr after irradiation of recipient mice (600 rads for Nude mice; 350 rads
for NOD-SCID mice). Antibiotics were added to drinking water for 14 days
following the procedure. At the end of each experiment, recipient mice were
anesthetized by i.p. injection of Avertin, and vasculature was exsanguinated
by perfusion of sterile PBS through the left ventricle.
Immunohistochemistry
Dissected tissues were fixed in 4% (WT/vol) paraformaldehyde 16–18 hr, em-
bedded in paraffin, and sectioned onto ProbeOn Plus microscope slides
(Fisher Scientific, Pittsburgh, PA) for immunohistochemistry using Vectastain
Elite ABC kits (Vector Laboratories, Burlingame, CA) as described (Sendobry
et al., 1997) (see Supplemental Data).
Flow Cytometric Analysis
Freshly harvested tissues were digested in 1 mg/ml collagenase A for 1–4 hr at
37C with continuous rotation. Resulting cell suspensions were dispersed with
an 18 g needle, washed 23with resuspension buffer (2% heat-inactivated fetal
calf serum in sterile HBBS) and filtered through 70 mm nylon mesh. Tissue cells
or BMCs were labeled for flow cytometry by incubation with appropriate anti-
bodies for 30 min, 1 hr at 4C with continuous rotation. Antibodies are PE-anti-
Ly-6A/E/Sca-1 clone E13-161.7 (400 ng/106 cells), APC-anti-CD117/c-Kit 2B8
(400 ng/106 cells), and mouse lineage panel kit (BD PharMingen).
ELISA
Mouse plasma was prepared by centrifugation of whole blood collected into
EDTA Microtainer tubes (BD PharMingen). Human OPN levels were measured
using species-specific TiterZyme EIA kits (Assay Designs) according to man-
ufacturer’s instructions.
OPN shRNA Plasmids
Five sequence-verified shRNA clones specific to human OPN were provided
in the pLKO.1-Puro lentivirus expression plasmid (Mission shRNA; Sigma,
St. Louis, MO). Infection and selection of target cells was performed as de-
scribed (Stewart et al., 2003). Only hairpins that suppressed OPN expression
without altering cell growth or morphology were used in subsequent experi-
ments (see Supplemental Data).
Analysis of Lung Metastases
Entire lungs were harvested and placed directly into sterile HBS, and GFP+
surface foci were counted under a dissecting microscope with fluorescence
capability. Discreet GFP+ foci that were visible under 43 magnification were
counted as micrometastases; GFP+ foci that were visible by naked eye were
counted as macrometastases.
Human Colon Tumor Specimens
Fresh surgical specimens of patient tumors were obtained with patient con-
sent from the Tissue Procurement Facility at Roswell Park Cancer Institute
shortly after resection and applied to the SCID mouse xenograft model as
described (Hylander et al., 2005; Naka et al., 2002) (Supplemental Data). The
tumor specimen that was used as a responder in the bilateral instigation
system was quickly thawed at 37C, washed 23 with RPMI, cut into 1–2 mm
segments and surgically implanted beneath the skin of NOD-SCID mice.
Statistical Analysis
Data are expressed as mean ± SEM. Data were analyzed by Student’s t test
and were considered statistically significant if p < 0.05.Cell 133, 994–1005, June 13, 2008 ª2008 Elsevier Inc. 1003
SUPPLEMENTAL DATA
Supplemental Data include eight figures, one table, Supplemental Experimen-
tal Procedures, and Supplemental References and can be found with this
article online at http://www.cell.com/cgi/content/full/133/6/994/DC1/.
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